Imprinted Gene Grading Model for Early Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic criteria for cancer rely heavily on morphological observation, which is experience-dependent and prone to misdiagnosis, especially in early stages where molecular changes precede visible morphological changes, necessitating a more sensitive and accurate diagnostic marker for early cancer detection.
Innovation Solution
A grading model for tumor diagnosis that calculates the expression status of imprinted genes, including Z16, Z19, and Z21, by assessing total, single-allelic, bi-allelic, and multi-allelic expression, providing a molecular basis for distinguishing benign and malignant tumors and monitoring tumor development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If morphological observation is used for cancer diagnosis, then diagnostic experience can be utilized, but misdiagnosis occurs especially in early stages due to lack of visible changes
Solution Approach 1:
The patent transitions from observing morphological parameters (cell shape, tissue structure) to detecting molecular parameters (methylation status of imprinted genes). This parameter change enables detection of epigenetic modifications that occur before morphological changes, thereby improving early cancer detection sensitivity while maintaining diagnostic reliability through standardized molecular markers.
Solution Approach 2:
The patent replaces the mechanical/visual observation system (pathologist microscopy examination) with a molecular detection system (methylation-specific PCR or similar molecular techniques). This substitution eliminates dependence on pathologist experience and provides objective, quantifiable measurements of gene methylation status, improving both accuracy and consistency in early cancer diagnosis.
2Measurement precision
If molecular markers are used for early cancer detection, then detection sensitivity is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts and focuses on a specific subset of molecular markers - imprinted genes with known cancer-associated methylation patterns (e.g., H19, MEST, PEG3). By selecting only these relevant genes rather than analyzing the entire genome, the patent maintains high detection sensitivity while reducing diagnostic complexity to a manageable panel of targeted markers.
Solution Approach 2:
The patent segments the complex task of cancer detection into analyzing specific imprinted genes individually, then integrating their methylation status to determine overall cancer risk. This segmentation allows systematic evaluation of multiple markers through a structured grading model, making the diagnostic process more organized and interpretable despite involving multiple genes.
3Reliability
If multiple imprinted genes are analyzed, then diagnostic specificity is improved, but detection time and resource requirements increase
Solution Approach 1:
The patent implements a graded diagnostic approach where the number of imprinted genes analyzed can be adjusted based on clinical needs. The core panel includes essential genes for basic cancer detection, while additional genes can be incorporated for enhanced specificity in complex cases. This partial action approach provides flexibility to balance diagnostic specificity against time and resource constraints.
Solution Approach 2:
The patent establishes a predetermined grading model with established thresholds and interpretation criteria for imprinted gene methylation patterns. By preparing this diagnostic framework in advance with predefined decision rules, the patent enables rapid interpretation of test results without requiring complex real-time analysis, thereby reducing detection time while maintaining high diagnostic specificity.
Data Source
AI summary
A grading model for detecting the benign and malignant degree of a tumor and an application thereof. A detection model is used for determining the benign and malignant degree of a tumor by intuitively observing a change of an imprinted gene of the tumor at an early stage at a single-cell and tissue level. Moreover, the type and the benign and malignant degree of the tumor can be accurately determined by combining expression changes of imprinted and non-imprinted genes.